Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
GB Gomez, M Siapka, F Conradie, N Ndjeka… - BMJ open, 2021 - bmjopen.bmj.com
Objectives Patients with highly resistant tuberculosis have few treatment options.
Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have …
Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have …
Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis
C Mulder, S Rupert, E Setiawan, E Mambetova… - BMJ global …, 2022 - gh.bmj.com
Introduction Bedaquiline, pretomanid and linezolid (BPaL) is a new all oral, 6-month
regimen comprised of bedaquiline, the new drug pretomanid and linezolid, endorsed by the …
regimen comprised of bedaquiline, the new drug pretomanid and linezolid, endorsed by the …
Incremental cost effectiveness of bedaquiline for the treatment of rifampicin-resistant tuberculosis in South Africa: model-based analysis
Background Nearly 20,000 people were diagnosed with multi-drug and rifampicin-resistant
tuberculosis (MDR/RR-TB) in South Africa in 2015, yet only one-half of the patients who start …
tuberculosis (MDR/RR-TB) in South Africa in 2015, yet only one-half of the patients who start …
Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries
X Lu, C Smare, C Kambili, AC El Khoury… - BMC health services …, 2017 - Springer
Background Less than one-third of patients who are estimated to be infected with multidrug-
resistant tuberculosis (MDR-TB) receive MDR-TB treatment regimens, and only 48% of …
resistant tuberculosis (MDR-TB) receive MDR-TB treatment regimens, and only 48% of …
Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a …
L Rosu, JJ Madan, EM Tomeny, M Muniyandi… - The Lancet Global …, 2023 - thelancet.com
Background The STREAM stage 2 trial assessed two bedaquiline-containing regimens for
rifampicin-resistant tuberculosis: a 9-month all-oral regimen and a 6-month regimen …
rifampicin-resistant tuberculosis: a 9-month all-oral regimen and a 6-month regimen …
Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa
Optimal treatment regimens for patients with extensively drug-resistant tuberculosis (XDR-
TB) remain unclear. Long-term prospective outcome data comparing XDR-TB regimens with …
TB) remain unclear. Long-term prospective outcome data comparing XDR-TB regimens with …
Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid
J Timm, A Bateson, P Solanki, A Paleckyte… - PLOS Global Public …, 2023 - journals.plos.org
Bedaquiline (B), pretomanid (Pa) and linezolid (L) are key components of new regimens for
treating rifampicin-resistant tuberculosis (TB). However, there is limited information on the …
treating rifampicin-resistant tuberculosis (TB). However, there is limited information on the …
The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa
A Mpobela Agnarson, A Williams… - Expert Review of Anti …, 2020 - Taylor & Francis
Background: Bedaquiline-containing regimens have demonstrated improved outcomes over
injectable-containing regimens in the long-term treatment of multidrug-resistant tuberculosis …
injectable-containing regimens in the long-term treatment of multidrug-resistant tuberculosis …
Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK
LJ Wolfson, A Walker, R Hettle, X Lu, C Kambili… - PLoS …, 2015 - journals.plos.org
Objective To evaluate the cost-effectiveness of adding bedaquiline to a background regimen
(BR) of drugs for multidrug-resistant tuberculosis (MDR-TB) in the United Kingdom (UK) …
(BR) of drugs for multidrug-resistant tuberculosis (MDR-TB) in the United Kingdom (UK) …
Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few,
and regimens are often long and poorly tolerated. Following recent evidence from the TB …
and regimens are often long and poorly tolerated. Following recent evidence from the TB …